TELA Bio Reports FDA 510(k) Clearance for Fully Resorbable Liora Surgical Mesh
Published in Tools.
Published October 6, 2026. Source date: October 5, 2026.
TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh intended to reinforce soft tissue.
The company describes Liora as the first implant developed entirely in its ISO 8-certified cleanroom in Malvern, Pennsylvania, and the first fully resorbable synthetic product in its portfolio designed and produced in-house.
TELA Bio expects to provide further details during its third-quarter earnings call in early November. The announcement does not provide comparative clinical outcomes, resorption timelines or detailed launch plans; it therefore does not establish superiority over other surgical meshes.
Source: TELA Bio official announcement.